Data on 968 diabetes patients who had percutaneous coronary intervention revealed those who used paclitaxel-eluting stents had higher thrombosis rates at six and 12 months and higher mortality at one year compared with those who were treated with everolimus-eluting stents. The findings appear in Catheterization and Cardiovascular Interventions.

Related Summaries